Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
27 hedge funds and large institutions have $12.7M invested in Cymabay Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 26 → 27 (+1)
2% more capital invested
Capital invested by funds: $12.4M → $12.7M (+$266K)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$34.2K |
| 2 |
Goldman Sachs
New York
|
+$32.9K |
| 3 |
Barclays
London,
United Kingdom
|
+$22.9K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.88K |
| 5 |
Morgan Stanley
New York
|
+$2.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$606K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$436K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$52.2K |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$52K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$48.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $1K | +$674 | +339 | +446% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $1K | +$770 | +387 | New |
|
|
UCFA
28
United Capital Financial Advisors
Irving,
Texas
| – | -$52K | -25,920 | Closed |
|
CBAY Hedge Fund Activity: Q3 2016 in Review
27 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2016, worth a combined $12.7M — up 2.1% from $12.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CBAY positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 11 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $34.2K. The largest seller was Omega Fund Management, cutting an estimated $606K.
- 27 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2016, up from 26 in Q2 2016.
- Funds reported $12.7M of Cymabay Therapeutics stock for Q3 2016, up 2.1% quarter-over-quarter.
- 4 funds opened new Cymabay Therapeutics positions in Q3 2016 and 3 closed out, a net change of +1 holder.
- The largest Cymabay Therapeutics buyer in Q3 2016 was Virtu KCG Holdings, an estimated $34.2K added.
- The largest Cymabay Therapeutics seller in Q3 2016 was Omega Fund Management, an estimated $606K sold.
Based on aggregated 13F filings for Q3 2016.